Tirzepatide + Cagrilintide
Also known as: Tirz + Cagri, Dual-Agonist + Amylin Stack
A weight-loss stack adding an amylin-based satiety signal on top of a dual GLP-1/GIP incretin agonist.
Components
How it's combined
Research framing combines tirzepatide (GLP-1/GIP dual agonist; FDA-approved for obesity as Zepbound) with cagrilintide (amylin analog) to add a separate fullness pathway tirzepatide does not directly hit. Notably, this specific pairing is compounded/experimental with no Phase 3 data; the validated amylin combination is CagriSema. Once-weekly subcutaneous in practice.
Available from vendors
PeptideChat is an independent research resource, not the seller. Links go to third-party vendors; products are sold strictly as research chemicals and are not intended for human consumption.
Independent research resource
Not a seller — PeptideChat doesn't sell or ship products.
Research-use-only framing
Content is educational, not a dosing recommendation.
Vendor links clearly disclosed
Outbound links to third-party vendors are always labeled.